Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TsumuraFRA:TSUA +1.02%69 OCF Margin % is 43.58% as of Mar. 2026, which is 205% above its 10-year median of 14.30. GuruFocus rates FRA:TSUA with a GF Score™ of 69/100 and a GF Value™ of €21.71 (Fairly Valued). The stock has 4 warning signs investors should review. Among 964 Drug Manufacturers companies, Tsumura ranks better than 59.54% on this metric.
The historical data trend for Tsumura's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Tsumura's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tsumura OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tsumura's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Tsumura's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tsumura (FRA:TSUA) has a OCF Margin % of 43.58% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Tsumura and its competitors. This is 205% above median its historical median of 14.30. Over the past decade, Tsumura's OCF Margin % has ranged from 3.72 to 18.68. According to the industry distribution chart, Tsumura ranks #390 out of 964 companies in the Drug Manufacturers industry, placing it in the top 40.5%.
Is Tsumura's OCF Margin % too high?
Tsumura's current OCF Margin % of 43.58% is 205% above median its 10-year median of 14.30. Over the past 10 years, this metric has ranged from a low of 3.72 to a high of 18.68. The Drug Manufacturers industry median OCF Margin % is 10.03. Tsumura's value of 43.58% is 334.7% above this industry median. Based on the distribution chart, Tsumura ranks #390 out of 964 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Tsumura has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tsumura's OCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Tsumura ranks #390 out of 964 companies for OCF Margin %. This puts Tsumura in the upper half of its industry. The industry median OCF Margin % is 10.03. Tsumura's value of 43.58% is 334.7% above this benchmark. Historically, Tsumura's own OCF Margin % has ranged from 3.72 to 18.68 over the past decade. While the company's 10-year median is 14.30 vs. the industry median of 10.03, Tsumura has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 10.03, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tsumura's current OCF Margin % of 43.58% is 334.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Tsumura and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 10.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tsumura's current OCF Margin % is 43.58%, which is 205% above median its own 10-year median of 14.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tsumura stock overvalued right now?
Based on GuruFocus' analysis, Tsumura (FRA:TSUA) is currently considered Fairly Valued. The stock's GF Value™ is €21.71, compared to a current price of €19.80 — trading 8.8% below its estimated fair value. The current OCF Margin % is 43.58%, which is 205% above median its 10-year median of 14.30 and 334.7% above the Drug Manufacturers industry median of 10.03. Tsumura's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Tsumura (FRA:TSUA), the current OCF Margin % is 43.58% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tsumura (FRA:TSUA) Overvalued in 2026?
Based on GuruFocus' analysis, Tsumura stock appears to be undervalued.
The current stock price of €19.80 is trading 8.8% below its estimated GF Value™ of €21.71.
GuruFocus considers Tsumura to be Fairly Valued.
Key valuation signals for FRA:TSUA:
OCF Margin %: 43.58% (205% above median its 10-year median of 14.30)
GF Value™: €21.71 vs. price of €19.80 (8.8% below fair value)
Industry Position: 334.7% above the Drug Manufacturers median (#390 of 964)
No single metric tells the full story. See the FRA:TSUA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tsumura & Co is a specialty and generic drug manufacturing company. The company generates the majority of its revenue through prescription Kampo products, followed by over-the-counter medicines. It promotes its products through educational support at medical schools and by hosting seminars for physicians and consumers. The company specializes in developing, producing, and marketing Kampo formulations that integrate traditional herbal knowledge with modern pharmaceutical science to address various health conditions.
69GF Score
Get the complete analysis for FRA:TSUA
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:TSUA has been successfully added to your 
